PHASE I TRIAL OF SUPER-SELECTIVE INTRAARTERIAL CEREBRAL INFUSION OF CETUXIMAB (ERBITUX) FOR TREATMENT OF RELAPSED/REFRACTORY GLIOBLASTOMA MULTIFORME AND ANAPLASTIC ASTROCYTOMA

Trial Profile

PHASE I TRIAL OF SUPER-SELECTIVE INTRAARTERIAL CEREBRAL INFUSION OF CETUXIMAB (ERBITUX) FOR TREATMENT OF RELAPSED/REFRACTORY GLIOBLASTOMA MULTIFORME AND ANAPLASTIC ASTROCYTOMA

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Feb 2017

At a glance

  • Drugs Cetuximab (Primary)
  • Indications Anaplastic astrocytoma; Astrocytoma; Glioblastoma
  • Focus Adverse reactions
  • Most Recent Events

    • 12 Dec 2016 Status changed from active, no longer recruiting to completed.
    • 23 Oct 2015 Planned End Date changed from 1 Dec 2013 to 1 Dec 2017 as reported by ClinicalTrials.gov record.
    • 23 Oct 2015 Planned primary completion date changed from 1 Dec 2013 to 1 Dec 2017 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top